BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 12527893)

  • 1. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
    Wang J; Knauf JA; Basu S; Puxeddu E; Kuroda H; Santoro M; Fusco A; Fagin JA
    Mol Endocrinol; 2003 Jul; 17(7):1425-36. PubMed ID: 12690093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.
    Chua EL; Wu WM; Tran KT; McCarthy SW; Lauer CS; Dubourdieu D; Packham N; O'Brien CJ; Turtle JR; Dong Q
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2733-9. PubMed ID: 10946873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
    Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
    Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice.
    Santoro M; Chiappetta G; Cerrato A; Salvatore D; Zhang L; Manzo G; Picone A; Portella G; Santelli G; Vecchio G; Fusco A
    Oncogene; 1996 Apr; 12(8):1821-6. PubMed ID: 8622903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
    Melillo RM; Castellone MD; Guarino V; De Falco V; Cirafici AM; Salvatore G; Caiazzo F; Basolo F; Giannini R; Kruhoffer M; Orntoft T; Fusco A; Santoro M
    J Clin Invest; 2005 Apr; 115(4):1068-81. PubMed ID: 15761501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
    Basolo F; Giannini R; Monaco C; Melillo RM; Carlomagno F; Pancrazi M; Salvatore G; Chiappetta G; Pacini F; Elisei R; Miccoli P; Pinchera A; Fusco A; Santoro M
    Am J Pathol; 2002 Jan; 160(1):247-54. PubMed ID: 11786418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
    Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells.
    Castellone MD; Celetti A; Guarino V; Cirafici AM; Basolo F; Giannini R; Medico E; Kruhoffer M; Orntoft TF; Curcio F; Fusco A; Melillo RM; Santoro M
    Oncogene; 2004 Mar; 23(12):2188-96. PubMed ID: 14981541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells.
    Miyagi E; Braga-Basaria M; Hardy E; Vasko V; Burman KD; Jhiang S; Saji M; Ringel MD
    Mol Carcinog; 2004 Oct; 41(2):98-107. PubMed ID: 15378648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
    Celetti A; Cerrato A; Merolla F; Vitagliano D; Vecchio G; Grieco M
    Oncogene; 2004 Jan; 23(1):109-21. PubMed ID: 14712216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
    Sugg SL; Zheng L; Rosen IB; Freeman JL; Ezzat S; Asa SL
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3360-5. PubMed ID: 8784097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
    Knauf JA; Kuroda H; Basu S; Fagin JA
    Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
    Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
    Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.